会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME
    • 包含HMG-COA还原酶和阿司匹林的抑制剂的组合制剂及其制备方法
    • WO2009022821A3
    • 2009-04-09
    • PCT/KR2008004623
    • 2008-08-08
    • HANALL PHARMACEUTICAL CO LTDKIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSUN SANG OUK
    • KIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSUN SANG OUK
    • A61K31/35
    • A61K31/35A61K31/616A61K45/06A61K2300/00
    • The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
    • 本发明涉及一种用于预防和治疗心血管疾病的时间疗法组合药物制剂,其基于以特定时间间隔施用多种药物的原则(即时间疗法)。 具体地,组合的药物制剂包含HMG-CoA还原酶抑制剂,例如辛伐他汀和阿司匹林。 因为组合的药物制剂是基于以特定时间间隔给药药物的原理而开发的,即所谓的时间疗法,与单独给药和单次制剂同时给药相比,它显示了预防或治疗心血管疾病的优异效果。 此外,它是一种每日一次的剂型,其增加患者的药物依从性。 特别是,尽管组合药物制剂中阿司匹林的含量降低,但组合药物制剂中阿司匹林的血小板聚集抑制作用等于现有技术中所用阿司匹林的量,而组合药物中阿司匹林 制剂显示抗高血压作用。 另外,按时间顺序组合的药物制剂允许两种彼此相互作用的药物长时间储存​​,并且组合的药物制剂确保了两种药物的人体安全性和功效。
    • 6. 发明申请
    • COMPOSITE PREPARATION
    • 复合制剂
    • WO2009104932A2
    • 2009-08-27
    • PCT/KR2009000832
    • 2009-02-21
    • HANALL PHARMACEUTICAL CO LTDKIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSUN SANG OUK
    • KIM SUNG WUKJUN SUNG SOOJO YOUNG GWANKOO JA SEONGSUN SANG OUK
    • A61K9/52
    • A61K9/2077A61K9/2009A61K9/2018A61K9/2027A61K9/2031A61K9/2054A61K9/2059A61K9/2081A61K9/209A61K9/2866A61K9/4808A61K9/5078A61K9/5084A61K31/4365A61K31/60A61K31/616A61K2300/00
    • The present invention provides a composite preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The composite preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin. The composite preparation of the present invention is also advantageous in that it exhibits an outstanding effect in inhibiting blood platelet aggregation despite a reduction in the amount of aspirin ingested, and in that it converts clopidogrel resistance into susceptibility and prevents serious adverse reactions caused by clopidogrel resistance and in that it can be stored over the longer term since it is stable under common storage conditions.
    • 本发明提供一种复合制剂,其包括:包含阿司匹林或其药学上可接受的盐作为药理活性成分的预释放部分; 以及包含氯吡格雷,其异构体或其药学上可接受的盐作为药理活性成分的延迟释放部分。 本发明的复合制剂与单独使用的制剂同时进行口服治疗或治疗相比,具有更好的预防血小板聚集效果,并且不仅可以通过一天一次的给药来改善患者的药物依从性,而且还可以 减少长期服用阿司匹林后的不良反应。 本发明的复合制剂的优点还在于,尽管阿司匹林的摄入量减少,但其表现出抑制血小板聚集的突出效果,并且其将氯吡格雷耐药性转化为易感性并防止由氯吡格雷抗性引起的严重不良反应 并且由于它在通常的储存条件下是稳定的,因此可以长期储存。